How Has the Leqvio Market Size Evolved in Recent Years?
The leqvio market has seen considerable growth due to a variety of factors.
• The size of the Leqvio market has shown an XX (HCAGR) expansion in the previous years. The estimated growth sees an ascension from $XX million in 2024 to $XX million in 2025, marking a Compound Annual Growth Rate (CAGR) of XX%.
The historical growth has been prompted by escalated funding in RNA-influenced drug advancements, more expenditures towards cholesterol regulation drugs, surged investments in research and medicinal development, augmented healthcare consciousness, and a mounting requirement for targeted medication.
What are the Market Size and Expected Growth Rates for the Leqvio Market?
The leqvio market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipations suggest that the forthcoming years will witness a significant surge in the leqvio market size with an expected XX (FCAGR). Its growth is projected to reach $XX million by 2029, with a compound annual growth rate (CAGR) of XX%.
The projected escalation during this period is chiefly attributed to an intensifying occurrence of cardiovascular diseases worldwide, rising awareness about the superior effectiveness of PCSK9 inhibitors, augmenting instances of high cholesterol, increase in the elderly population, and the expansion of biologic drugs. Noteworthy trends during this period enclose an escalating demand for refined treatments for hypercholesterolemia, broadening indications through active research, incessant approvals from regulatory authorities like the FDA, breakthroughs in biopharmaceutical research, and advancements in pharmaceutical development.
Which Key Drivers Are Propelling The Leqvio Market's Growth?
The surging instance of cardiovascular diseases is projected to spur the expansion of the leqvio market in the future. A variety of conditions impacting the heart and blood vessels collectively form cardiovascular diseases, often leading to serious health problems like heart attacks, strokes, or hypertension. The onset of these diseases can be attributed to various factors such as unhealthy eating habits, lack of physical activity, excessive alcohol intake, diabetes, and ageing. Leqvio functions by inhibiting the PCSK9 protein, thereby improving the liver's capacity to rid the blood of LDL cholesterol. This aids in reducing LDL levels, consequently decreasing the likelihood of heart attacks, strokes, and other cardiovascular events. For example, in September 2024, data released by the British Heart Foundation, a cardiovascular research charity based in the UK, revealed that roughly 7.6 million people in the UK are affected by heart and circulatory conditions, comprising of around 4 million males and 3.6 million females. These diseases account for nearly 27% of all UK deaths, resulting into over 170,000 deaths yearly, or approximately 480 deaths per day, which means one death every three minutes. Hence, the escalating incidence of cardiovascular diseases fuels the growth of the Leqvio market.
What Are The Key Segments Within The Global Leqvio Market?
The leqvio market covered in this report is segmented –
1) By Formulation: Injectable Formulation (Subcutaneous), Pre-Filled Syringes Or Auto-Injectors
2) By Indication: Treatment Of Hyperlipidemia, Management Of Atherosclerotic Cardiovascular Disease (ASCVD), Treatment Of Familial Hypercholesterolemia
3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients with Comorbid Conditions
4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Cardiovascular Clinics, Specialty Pharmacies, Home Healthcare Providers
Pre-Book The Leqvio Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Leqvio Market?
A primary trend observed in the Leqvio market revolves around the manufacture of advanced injectable prescription drugs designed to provide long-lasting treatments, thus improving patient compliance and outcomes. These injectable prescription medications are typically for management of high cholesterol and mitigation of cardiovascular risks, usually administered at consistent periods to maintain a sustained therapeutic impact. For instance, in July 2023, Novartis, a pharmaceutical company located in Switzerland, obtained approval from the US Food and Drug Administration (FDA) for a label update on Leqvio (inclisiran), thus permitting its application at an earlier phase for patients with increased LDL-C levels and a heightened risk of heart disease. This would be in conjunction with diet and statin therapy. With two shots given every year after two initial doses, the medicine provides an up to 52% LDL-C reduction and has been shown to effectively help patients who haven't achieved their LDL-C target even after statin therapy. The updated labelling emphasizes the solid safety and effectiveness details supported by the VictORION clinical trial program.
Who Are the Key Players In The Leqvio Market?
Major companies operating in the leqvio market include:
• Novartis AG
What Are The Regional Insights Into The Leqvio Market?
North America was the largest region in the leqvio market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
